세계의 의약품 첨가제 시장 규모, 성장률, 동향 분석 : 기능, 용도, 제품별 예측(-2032년)

Global Pharmaceutical Excipients Market Size, Growth and Trends Analysis by Function (Pharmaceutical Fillers, Binders, Coatings, Disintegrants, Preservatives, Others), Application (Oral, Parenteral, Topical, Others), Product (Organic Chemicals, Inorganic Chemicals) - Industry Forecast 2032

Market Snapshot

The size of the pharmaceutical excipients market was estimated at USD 9.27 billion in 2023 and is expected to increase at a compound annual growth rate (CAGR) of 7.03% from 2024 to 2032, from USD 10.02 billion in 2024 to USD 18.48 billion by 2032. The growing need for multifunctional excipients and the growing use of generic drugs are the primary factors propelling market expansion.

Furthermore, the market for pharmaceutical excipients is used to enhance the medication's flavor, which increases patient compliance, especially in young patients. Pharmaceutical excipients can come from both organic and inorganic sources, depending on their chemical composition. The growing need for functional excipients, recent patent expirations that increase consumer demand for pharmaceutical excipients, and the rapid advancement of nanotechnology are the primary factors propelling the pharmaceutical excipients market. For long-term stabilization, to increase the potency of the active ingredient in the final dosage form, or for any other purpose, excipients can be added to solid formulations that contain small APIs. Additionally, excipients are used to improve the properties of medicinal formulations, including increasing API solubility, decreasing viscosity, and improving drug absorption.

Market Segments Insights

Pharmaceutical fillers, binders, coatings, disintegrants, preservatives, and others are among the market sectors for pharmaceutical excipients based on their operational roles.

By-products have been separated into organic and inorganic compounds according to market data for pharmaceutical excipients.

The pharmaceutical excipients market has been divided into several segments based on applications, including parenteral, topical, and oral.

Regional Perspectives

The market insights by region in the survey encompass Asia-Pacific, Europe, North America, and the rest of the globe. The pharmaceutical excipients market in Europe was estimated to be worth USD 2.51 billion in 2022 and was projected to grow at a significant compound annual growth rate. Many European nations concentrate on the generics industry because of the approaching expiration dates of pharmaceutical patents. Therefore, it is expected that European nations such as Germany, the United Kingdom, France, and others will have notable growth rates over the forecast period. Pharmaceutical excipients are expected to become more and more necessary in the region.

North America has the second-largest proportion of the pharmaceutical excipients market. Over the course of the projection period, the market is expected to increase significantly due to the quickly increasing pharmaceutical sector, rising demand for functional excipients, strong competitors in the industry, and technological advancements.

The Asia-Pacific pharmaceutical excipients market is projected to grow at the fastest compound annual growth rate (CAGR) from 2024 to 2032. According to a recent study, China's overall revenue from traditional pharmaceutical sales is expected to increase over the coming years.

Key Players

Evonik Industries Ag, Basf Se, Ferro Corporation, P&G Chemicals, Akzo Nobel NV, FMC Corporation, The Dow Chemical Company, Ashland, Inc., and Croda International PLC are a few of the major players in the pharmaceutical excipients industry.

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

• 2.1. DEFINITION
• 2.2. SCOPE OF THE STUDY
  • 2.2.1. RESEARCH OBJECTIVE
  • 2.2.2. ASSUMPTIONS
  • 2.2.3. LIMITATIONS

3. RESEARCH METHODOLOGY

• 3.1. OVERVIEW
• 3.2. DATA MINING
• 3.3. SECONDARY RESEARCH
• 3.4. PRIMARY RESEARCH
  • 3.4.1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
  • 3.4.2. BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5. FORECASTING TECHNIQUE
• 3.6. MARKET SIZE ESTIMATION
  • 3.6.1. BOTTOM-UP APPROACH
  • 3.6.2. TOP-DOWN APPROACH
• 3.7. DATA TRIANGULATION
• 3.8. VALIDATION

4. MARKET DYNAMICS

• 4.1. OVERVIEW
• 4.2. DRIVERS
• 4.3. RESTRAINTS
• 4.4. OPPORTUNITIES

5. MARKET FACTOR ANALYSIS

• 5.1. VALUE CHAIN ANALYSIS
• 5.2. PORTER'S FIVE FORCES ANALYSIS
  • 5.2.1. BARGAINING POWER OF SUPPLIERS
  • 5.2.2. BARGAINING POWER OF BUYERS
  • 5.2.3. THREAT OF NEW ENTRANTS
  • 5.2.4. THREAT OF SUBSTITUTES
  • 5.2.5. INTENSITY OF RIVALRY
• 5.3. COVID-19 IMPACT ANALYSIS
  • 5.3.1. MARKET IMPACT ANALYSIS
  • 5.3.2. REGIONAL IMPACT
  • 5.3.3. OPPORTUNITY AND THREAT ANALYSIS

6. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE

• 6.1. OVERVIEW
• 6.2. PHARMACEUTICAL FILLERS
• 6.3. BINDERS
• 6.4. COATINGS
• 6.5. DISINTEGRANTS
• 6.6. PRESERVATIVES
• 6.7. OTHERS

7. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT

• 7.1. OVERVIEW
• 7.2. ORGANIC CHEMICALS
• 7.3. INORGANIC CHEMICALS

8. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET, BY APPLICATION

• 8.1. OVERVIEW
• 8.2. ORAL
• 8.3. TOPICAL
• 8.4. PARENTERAL
• 8.5. OTHERS

9. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION

• 9.1. OVERVIEW
• 9.1. NORTH AMERICA
  • 9.1.1. US
  • 9.1.2. CANADA
• 9.2. EUROPE
  • 9.2.1. GERMANY
  • 9.2.2. FRANCE
  • 9.2.3. UK
  • 9.2.4. ITALY
  • 9.2.5. SPAIN
  • 9.2.6. REST OF EUROPE
• 9.3. ASIA-PACIFIC
  • 9.3.1. CHINA
  • 9.3.2. INDIA
  • 9.3.3. JAPAN
  • 9.3.4. SOUTH KOREA
  • 9.3.5. AUSTRALIA
  • 9.3.6. REST OF ASIA-PACIFIC
• 9.4. REST OF THE WORLD
  • 9.4.1. MIDDLE EAST
  • 9.4.2. AFRICA
  • 9.4.3. LATIN AMERICA

10. COMPANY LANDSCAPE

• 10.1. OVERVIEW
• 10.2. COMPETITIVE ANALYSIS
• 10.3. MARKET SHARE ANALYSIS
• 10.4. MAJOR GROWTH STRATEGY IN THE GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET
• 10.5. COMPETITIVE BENCHMARKING
• 10.6. LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET
• 10.7. KEY DEVELOPMENTS AND GROWTH STRATEGIES
  • 10.7.1. NEW PRODUCT LAUNCH
  • 10.7.2. MERGER & ACQUISITIONS
  • 10.7.3. JOINT VENTURES
• 10.8. MAJOR PLAYERS FINANCIAL MATRIX
  • 10.8.1. SALES & OPERATING INCOME,
  • 10.8.2. MAJOR PLAYERS R&D EXPENDITURE.

11. COMPANY PROFILES

• 11.1. EVONIK INDUSTRIES AG
  • 11.1.1. COMPANY OVERVIEW
  • 11.1.2. FINANCIAL OVERVIEW
  • 11.1.3. PRODUCT OFFERED
  • 11.1.4. KEY DEVELOPMENTS
  • 11.1.5. SWOT ANALYSIS
  • 11.1.6. KEY STRATEGIES
• 11.2. BASF SE
  • 11.2.1. COMPANY OVERVIEW
  • 11.2.2. FINANCIAL OVERVIEW
  • 11.2.3. PRODUCT OFFERED
  • 11.2.4. KEY DEVELOPMENTS
  • 11.2.5. SWOT ANALYSIS
  • 11.2.6. KEY STRATEGIES
• 11.3. FERRO CORPORATION
  • 11.3.1. COMPANY OVERVIEW
  • 11.3.2. FINANCIAL OVERVIEW
  • 11.3.3. PRODUCT OFFERED
  • 11.3.4. KEY DEVELOPMENTS
  • 11.3.5. SWOT ANALYSIS
  • 11.3.6. KEY STRATEGIES
• 11.4. P&G CHEMICALS
  • 11.4.1. COMPANY OVERVIEW
  • 11.4.2. FINANCIAL OVERVIEW
  • 11.4.3. PRODUCT OFFERED
  • 11.4.4. KEY DEVELOPMENTS
  • 11.4.5. SWOT ANALYSIS
  • 11.4.6. KEY STRATEGIES
• 11.5. FMC CORPORATION
  • 11.5.1. COMPANY OVERVIEW
  • 11.5.2. FINANCIAL OVERVIEW
  • 11.5.3. PRODUCT OFFERED
  • 11.5.4. KEY DEVELOPMENTS
  • 11.5.5. SWOT ANALYSIS
  • 11.5.6. KEY STRATEGIES
• 11.6. THE DOW CHEMICAL COMPANY
  • 11.6.1. COMPANY OVERVIEW
  • 11.6.2. FINANCIAL OVERVIEW
  • 11.6.3. PRODUCT OFFERED
  • 11.6.4. KEY DEVELOPMENTS
  • 11.6.5. SWOT ANALYSIS
  • 11.6.6. KEY STRATEGIES
• 11.7. ASHLAND, INC.
  • 11.7.1. COMPANY OVERVIEW
  • 11.7.2. FINANCIAL OVERVIEW
  • 11.7.3. PRODUCT OFFERED
  • 11.7.4. KEY DEVELOPMENTS
  • 11.7.5. SWOT ANALYSIS
  • 11.7.6. KEY STRATEGIES
• 11.8. CRODA INTERNATIONAL PLC
  • 11.8.1. COMPANY OVERVIEW
  • 11.8.2. FINANCIAL OVERVIEW
  • 11.8.3. PRODUCT OFFERED
  • 11.8.4. KEY DEVELOPMENTS
  • 11.8.5. SWOT ANALYSIS
  • 11.8.6. KEY STRATEGIES
• 11.9. AKZO NOBEL NV
  • 11.9.1. COMPANY OVERVIEW
  • 11.9.2. FINANCIAL OVERVIEW
  • 11.9.3. PRODUCT OFFERED
  • 11.9.4. KEY DEVELOPMENTS
  • 11.9.5. SWOT ANALYSIS
  • 11.9.6. KEY STRATEGIES
• 11.10. INNOPHOS
  • 11.10.1. COMPANY OVERVIEW
  • 11.10.2. FINANCIAL OVERVIEW
  • 11.10.3. PRODUCT OFFERED
  • 11.10.4. KEY DEVELOPMENTS
  • 11.10.5. SWOT ANALYSIS
  • 11.10.6. KEY STRATEGIES

12. APPENDIX

• 12.1. REFERENCES
• 12.2. RELATED REPORTS